Target intelligence / Profile preview

Estrogen receptor (ER)–Human epidermal growth factor receptor 2 (HER2) signaling axis (ER–HER2 axis)

Target
ER–HER2 axis
Molecular classification
Receptor, Transcription factor, Receptor tyrosine kinase, Other
01

Overview

The Estrogen receptor (ER)–Human epidermal growth factor receptor 2 (HER2) signaling axis is a critical regulatory network in breast cancer characterized by bidirectional crosstalk between the ER and HER2 pathways (Arpino et al., 2008, Breast Cancer Research). In this axis, HER2-mediated activation of downstream cascades, such as the MAPK and PI3K/Akt pathways, can lead to the phosphorylation and activation of ER and its coactivators, allowing for estrogen-independent tumor growth and survival (Schiff et al., 2004, Journal of Clinical Oncology). Conversely, ER signaling can transcriptionally regulate the expression of HER2 and other EGFR family members, creating a feedback loop that promotes therapeutic resistance (Giuliano et al., 2011, Clinical Cancer Research). This interaction is a primary mechanism of resistance to endocrine therapies like tamoxifen, as the tumor cell can bypass ER inhibition by upregulating growth factor signaling. Clinical management of tumors driven by this axis often requires a "dual blockade" strategy, using combinations of endocrine agents and HER2-targeted therapies to effectively shut down both survival pathways and improve patient outcomes (Johnston et al., 2009, Journal of Clinical Oncology).

Other names
ER/HER2 crosstalkER-HER2 bidirectional signalingEstrogen receptor-ERBB2 axisER-HER2 pathway
02

Mechanism of action

The therapeutic mechanism involves the simultaneous inhibition of the genomic and non-genomic actions of the Estrogen Receptor (ER) and the kinase activity or dimerization of the HER2 receptor. This dual blockade disrupts the bidirectional crosstalk where HER2 signaling activates ER in a ligand-independent manner and ER signaling upregulates HER2 pathway components (Arpino et al., 2008, Breast Cancer Research). By targeting both nodes, therapies aim to overcome endocrine resistance and prevent the activation of alternative survival pathways (Schiff et al., 2004, Journal of Clinical Oncology).

03

Biological functions

Signal transductionCell proliferationGene expression regulationCell survival
04

Disease associations

Cancer
05

Safety considerations

Cardiotoxicity (specifically decreased Left Ventricular Ejection Fraction)Thromboembolic eventsEndometrial hyperplasiaSevere diarrhea (associated with TKIs)Acquired therapeutic resistance
06

Interacting drugs

Tamoxifen

9 more in the full profile.

07

Biomarkers

Estrogen receptor alpha (ERα) expressionHER2 protein overexpression (IHC 3+)HER2 gene amplification (FISH+)Phospho-ER (S118/S167)Phospho-MAPKPhospho-AKT

Beyond the preview

Go deeper on Estrogen receptor (ER)–Human epidermal growth factor receptor 2 (HER2) signaling axis (ER–HER2 axis).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Estrogen receptor (ER)–Human epidermal growth factor receptor 2 (HER2) signaling axis (ER–HER2 axis).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call